Clinical Trial Update: A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating venetoclax with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)
• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2021-06-30